相似文献
1
Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management.
Gut. 2006 Jun;55(6):886-93. doi: 10.1136/gut.2004.061663.
2
Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphomas: A review.
World J Gastroenterol. 2015 Jul 14;21(26):8014-20. doi: 10.3748/wjg.v21.i26.8014.
3
Gastric MALT lymphoma with t(14;18)(q32;q21) involving IGH and BCL2 genes that responded to Helicobacter pylori eradication.
J Clin Pathol. 2007 Oct;60(10):1171-3. doi: 10.1136/jcp.2007.048207.
4
[MALT gastric lymphoma].
Med Clin (Barc). 2003 Mar 15;120(9):349-52. doi: 10.1016/s0025-7753(03)73698-7.
5
Current status of gastric MALT lymphoma.
Curr Gastroenterol Rep. 2006 Oct;8(5):343-6. doi: 10.1007/s11894-006-0016-6.
6
Can DNA methylation be a molecular marker for eradication of Helicobacter pylori in MALT lymphoma?
J Gastroenterol. 2002 Jan;37(1):73-4. doi: 10.1007/s535-002-8138-1.
7
[Low-grade MALT gastric lymphomas: antibiotics or gastrectomy].
Rev Esp Enferm Dig. 1999 Jul;91(7):520-1.
8
Helicobacter pylori and t(11;18)(q21;q21) translocation in gastric malt lymphoma.
Arq Gastroenterol. 2014 Apr-Jun;51(2):84-9. doi: 10.1590/s0004-28032014000200003.
9
Gastric mucosal-associated lymphoid tissue lymphoma.
Gastroenterol Clin North Am. 2013 Jun;42(2):371-80. doi: 10.1016/j.gtc.2013.01.008. Epub 2013 Mar 15.
10
[Gastric lymphomas: role of Helicobacter pylori].
Presse Med. 1997 Feb 15;26(4):184-9.
引用本文的文献
1
-Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma in a Girl.
Case Rep Oncol. 2024 Feb 15;17(1):256-263. doi: 10.1159/000535999. eCollection 2024 Jan-Dec.
2
Clinical Management of Patients with Gastric MALT Lymphoma: A Gastroenterologist's Point of View.
Cancers (Basel). 2023 Jul 27;15(15):3811. doi: 10.3390/cancers15153811.
3
An Overview of Selected Bacterial Infections in Cancer, Their Virulence Factors, and Some Aspects of Infection Management.
Biology (Basel). 2023 Jul 5;12(7):963. doi: 10.3390/biology12070963.
4
Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal.
Ther Adv Med Oncol. 2023 Jun 22;15:17588359231183565. doi: 10.1177/17588359231183565. eCollection 2023.
5
Signaling pathways of oxidative stress response: the potential therapeutic targets in gastric cancer.
Front Immunol. 2023 Apr 18;14:1139589. doi: 10.3389/fimmu.2023.1139589. eCollection 2023.
6
Ten-day concomitant and sequential therapy for Helicobacter pylori effective in region with high antibiotic resistance rates.
Indian J Gastroenterol. 2022 Dec;41(6):627-633. doi: 10.1007/s12664-022-01272-1. Epub 2022 Dec 27.
7
Oncogenicity: Mechanism, Prevention, and Risk Factors.
ScientificWorldJournal. 2020 Jul 12;2020:3018326. doi: 10.1155/2020/3018326. eCollection 2020.
8
Gastrointestinal lymphoma: the new mimic.
BMJ Open Gastroenterol. 2019 Sep 13;6(1):e000320. doi: 10.1136/bmjgast-2019-000320. eCollection 2019.
9
Endoscopic features aiding the diagnosis of gastric mucosa-associated lymphoid tissue lymphoma.
Yeungnam Univ J Med. 2019 May;36(2):85-91. doi: 10.12701/yujm.2019.00136. Epub 2019 Feb 26.
10
Pathogenicity of Helicobacter pylori in cancer development and impacts of vaccination.
Gastric Cancer. 2019 Jan;22(1):23-36. doi: 10.1007/s10120-018-0867-1. Epub 2018 Aug 25.
本文引用的文献
1
Wotherspoon criteria combined with B cell clonality analysis by advanced polymerase chain reaction technology discriminates covert gastric marginal zone lymphoma from chronic gastritis.
Gut. 2006 Jun;55(6):782-7. doi: 10.1136/gut.2005.080523. Epub 2006 Jan 19.
2
Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H pylori eradication.
Gut. 2006 Jan;55(1):137-8. doi: 10.1136/gut.2005.081117.
3
FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations.
Leukemia. 2005 Aug;19(8):1299-305. doi: 10.1038/sj.leu.2403813.
4
Bcl10 can promote survival of antigen-stimulated B lymphocytes.
Blood. 2005 Sep 15;106(6):2105-12. doi: 10.1182/blood-2004-04-1248. Epub 2005 May 5.
5
Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21).
Blood. 2005 Aug 1;106(3):1037-41. doi: 10.1182/blood-2005-01-0004. Epub 2005 Apr 21.
6
Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial.
Med Oncol. 2005;22(1):57-62. doi: 10.1385/MO:22:1:057.
7
T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma.
Leukemia. 2005 Apr;19(4):652-8. doi: 10.1038/sj.leu.2403644.
8
MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression.
J Pathol. 2005 Feb;205(3):293-301. doi: 10.1002/path.1715.
9
Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy.
J Clin Oncol. 2005 Mar 20;23(9):1979-83. doi: 10.1200/JCO.2005.08.128. Epub 2005 Jan 24.
10
MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells.
Blood. 2005 Apr 1;105(7):2891-9. doi: 10.1182/blood-2004-06-2297. Epub 2004 Dec 14.
Zotero 插件